Restricted Content
On July 23, 2019, the United States District Court for the District of Columbia released this ruling on the motion for summary judgement in the case Braeburn v. FDA & Indivior. The ruling states that Braeburn’s motion is granted; and both Indivior’s motion, and the FDA’s motion, are denied. This decision challenges the FDA’s determination that Brixadi Monthly cannot be finally approved until Sublocade’s three-year exclusivity expires . . .
